Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-03-20
2007-03-20
Haddad, Maher M. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S192100, C514S002600, C530S324000
Reexamination Certificate
active
10633008
ABSTRACT:
The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer.
REFERENCES:
patent: 4579827 (1986-04-01), Sakamoto et al.
patent: 6410708 (2002-06-01), Ashkenazi et al.
patent: 0 199 141 (1986-10-01), None
patent: 0 616 812 (1994-09-01), None
patent: 0 616 812 (1994-09-01), None
patent: WO 00/29583 (2000-05-01), None
patent: WO 00/36102 (2000-06-01), None
patent: WO 00/53758 (2000-09-01), None
patent: WO 01/04311 (2001-01-01), None
patent: WO 01/40466 (2001-06-01), None
patent: WO 02/00690 (2002-01-01), None
patent: WO 02/08284 (2002-01-01), None
Walker MG. Z39Ig is co-expressed with activated macrophage genes. Biochim Biophys Acta. Apr. 12, 2002;1574(3):387-90.
Kahan BD. Immunosuppressive therapy. Curr Opin Immunol. Oct. 1992;4(5):553-60.
Kim et al. Characterization of monoclonal antibody specific to the Z39Ig protein, a member of immunoglobulin superfamily. Immunol Lett. Jul. 15, 2005;99(2):153-61.
Boyum, A. “A One Stage Procedure for Isolation of Granulocytes and Lymphocytes form Human Blood,” Norweigan Defense Establishment, Div. Of Toxicology, pp. 51-76.
Martin-Padura, I. et al, “Junctional Adhesion Molecule, aNovel Member of the Immunoglobulin Superfamily That Distributes at Intercellular Junctions and Modulates Monocyte Transmigration,” J. Cell Biol. 142(1): 117-27 (1998).
Monks, A. et al., “Feasibility of High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cel Lines,” Natl. Cancer Inst. 83: 757-766 (1991).
Skehan, P. et al., “New Colorimetric Cytoxicity Assay for Anticancer-Drug Screening,” J. Natl. Cancer Inst. 82: 1107-1112 (1990).
Spencer, S. et al., “The Orphan Receptor CRF2-4 is an Essential Subunit of the Interleukin 10 Recepto,” J. Exp. Med. 187: 571-578 (1998).
Taylor, S. et al., “The Human Homologue of Bub3 Is Required for Kinetochore Localization of Bub1 and a Mad3/Bub1-Related Protein Kinase,” J. Cell. Biol. 142(1): 1-11 (1998).
Welt, S. et al., “Quantative Analysis of Antibody Localization in Human Metastatic Colon Cancer: A Phase I Study of Monoclonal Antibody A33,” J. Clin. Oncol. 8: 1894-1906 (1990).
Welt, S. et al., “Phase I/II Study of Iodine 131-Labeled Monoclonal Antibody A33 in Patients with Advanced Colon Cancer,” J. Clin. Oncol. 12: 1561-1571 (1994).
Martin-Padura et al., “Junctional Adhesion Molecule, A Novel Member of the Immunoglobin Superfamily that Distributes at Intercellular Junctions and Modulates Monocyte Transmigration”, J. Cell Biology, vol. 142, No. 1, pp. 117-127, Jul. 13, 1998.
Ozaki et al, “Cutting Edge: Combined Treatment of the TNF-alpha and IFN-gamma causes Redistribution of Junctional Adhesion Molecule in Human Endothelial Cells”, J. Immunol., vol. 163, No. 2, Jul. 15, 1999.
Ashkenazi Avi
Fong Sherman
Goddard Audrey
Gurney Austin L.
Lookeren Menno Van
Barnes Elizabeth M.
Dreger, Esq. Ginger R.
Genentech Inc.
Haddad Maher M.
Kresnak Mark T.
LandOfFree
Treatment of inflammatory disorders with STIgMA immunoadhesins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of inflammatory disorders with STIgMA immunoadhesins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of inflammatory disorders with STIgMA immunoadhesins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3740201